Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu, Augustenburger Platz 1, 13353, Berlin, Germany.
German Cancer Consortium (DKTK), Berlin, Germany.
Cancer Immunol Immunother. 2023 Feb;72(2):515-521. doi: 10.1007/s00262-022-03264-8. Epub 2022 Aug 10.
Lymph node-infiltrating T cells have been of particular interest in classical Hodgkin lymphoma (cHL). High rates of complete therapeutic responses to antibody-mediated immune checkpoint blockade, even in relapsed/refractory patients, suggest the existence of a T cell-dominated, antigen-experienced, functionally inhibited and lymphoma-directed immune microenvironment. We asked whether clonally expanded T cells (1) were detectable in cHL lymph nodes, (2) showed characteristic immune phenotypes, and (3) were inhibited by immune checkpoint molecule expression. We applied high-dimensional FACS index sorting and single cell T cell receptor αβ sequencing to lymph node-infiltrating T cells from 10 treatment-naïve patients. T cells were predominantly CD4 and showed memory differentiation. Expression of classical immune checkpoint molecules (CTLA-4, PD-1, TIM-3) was generally low (< 12.0% of T cells) and not different between CD4 and CD8 T cells. Degrees of clonal T cell expansion varied between patients (range: 1-18 expanded clones per patient) and was almost exclusively restricted to CD8 T cells. Clonally expanded T cells showed non-naïve phenotypes and low checkpoint molecule expression similar to non-expanded T cells. Our data suggest that the therapeutic effects of immune checkpoint blockade require mechanisms in addition to dis-inhibition of pre-existing lymphoma-directed T cell responses. Future studies on immune checkpoint blockade-associated effects will identify molecular T cell targets, address dynamic aspects of cell compositions over time, and extend their focus beyond lymph node-infiltrating T cells.
淋巴结浸润 T 细胞在经典霍奇金淋巴瘤(cHL)中特别受到关注。抗体介导的免疫检查点阻断治疗反应率很高,即使在复发/难治性患者中也是如此,这表明存在以 T 细胞为主导、抗原经验丰富、功能受抑制且针对淋巴瘤的免疫微环境。我们想知道克隆扩增的 T 细胞 (1) 是否可在 cHL 淋巴结中检测到,(2) 是否表现出特征性的免疫表型,以及 (3) 是否受到免疫检查点分子表达的抑制。我们应用高维 FACS 指数分选和单细胞 T 细胞受体αβ测序对 10 例未经治疗的患者的淋巴结浸润 T 细胞进行了分析。T 细胞主要为 CD4,表现出记忆分化。经典免疫检查点分子(CTLA-4、PD-1、TIM-3)的表达一般较低(<12.0%的 T 细胞),且在 CD4 和 CD8 T 细胞之间没有差异。克隆性 T 细胞扩增的程度在患者之间有所不同(范围:每个患者 1-18 个扩增克隆),几乎完全局限于 CD8 T 细胞。克隆性扩增的 T 细胞表现出非幼稚表型和低检查点分子表达,与非扩增的 T 细胞相似。我们的数据表明,免疫检查点阻断的治疗效果需要除了抑制预先存在的淋巴瘤定向 T 细胞反应之外的机制。未来对免疫检查点阻断相关作用的研究将确定分子 T 细胞靶点,解决随着时间的推移细胞成分的动态方面,并将其重点扩展到淋巴结浸润 T 细胞之外。